MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
Pfizer Interest Expense 2011-2026 | PFE
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Pfizer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.67 B | 3.09 B | 2.21 B | 1.24 B | 1.29 B | 1.45 B | 1.57 B | 1.32 B | 1.27 B | 1.19 B | 1.2 B | 1.36 B | 1.41 B | 1.52 B | 1.68 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.09 B | 1.19 B | 1.63 B |
Quarterly Interest Expense Pfizer
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 668 M | 652 M | 654 M | 654 M | 783 M | 778 M | 790 M | 695 M | 508 M | 318 M | - | 311 M | 293 M | 322 M | - | 325 M | 316 M | 336 M | - | 345 M | 367 M | 390 M | - | 409 M | 389 M | 361 M | - | 310 M | 326 M | 310 M | - | 320 M | 312 M | 309 M | - | 291 M | 292 M | 306 M | - | 278 M | 278 M | 309 M | - | 343 M | 343 M | 321 M | - | 340 M | 356 M | 371 M | - | 381 M | 378 M | 390 M | - | 423 M | 404 M | 458 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 790 M | 278 M | 409 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
722 K | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B |  France |
 |
Athira Pharma
ATHA
|
1.24 M | - | - | $ 269 M | USA |
 |
Genprex
GNPX
|
38 K | $ 0.89 | 0.62 % | $ 830 K | USA |
 |
BioNTech SE
BNTX
|
14.2 M | $ 93.04 | -2.58 % | $ 27.2 B | Germany |
 |
INmune Bio
INMB
|
2.28 M | $ 1.48 | -3.9 % | $ 36.6 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
1.82 M | $ 22.79 | 1.95 % | $ 3.78 B | USA |
 |
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 3.6 | 2.86 % | $ 5.93 M |  Israel |
 |
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | USA |
 |
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
8 K | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
443 K | $ 23.55 | 0.56 % | $ 3 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
-27 K | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
86.6 M | $ 53.07 | 1.32 % | $ 4.77 B |  Schweiz |
 |
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
36.7 M | $ 1.69 | 2.74 % | $ 450 M |  Britain |
 |
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-93 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B |  Cayman-islands |